Dickinson Wright Attorneys recently tackled some basic questions regarding private equity in health care during Dickinson Wright’s Health Law Summit. Below is a summary of what was discussed. Click here to view the full webinar. What is private equity? The term “private equity” is broad, referring to family offices, limited partnerships, and investment funds put together for specific purposes, namely to invest in certain sectors. They come in many different sizes and forms, and a large segment is specifically set up for healthcare transactions. The majority are interested in one of two varieties of transaction – controlled transactions, where private equity…
Author: Praveen Suthrum
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes, a pioneer in the development of precision-based gastrointestinal disease technologies, announced today that it has entered into a collaboration with Janssen Research & Development, LLC (Janssen) in which Iterative Scopes will work with the Janssen Data Science and Immunology teams to augment Janssen’s clinical trials for inflammatory bowel disease (IBD) with the deployment of cutting-edge artificial intelligence (AI) and computer vision tools.
Bethesda, MD (January 20,2022) – AGA and Varia Ventures have launched a new fund to invest in fast-growing, early-stage companies in the GI space. The fund will speed innovations from concept to clinic for the benefit of patients with digestive disease. GI innovators often face a funding gap at the earliest stages of development; strategic investments of $250K to $2M could make their idea successful – but most venture capital (VC) firms do not fund such early-stage innovation. The GI Opportunity Fund seeks to fill that gap by connecting GI innovators with GI investors.
DALLAS, Jan. 20, 2022 /PRNewswire/ — GI Alliance, the nation’s largest independent gastroenterology services organization, is pleased to announce a partnership with Denver Digestive Health Specialists. This alignment expands GI Alliance’s Colorado presence by combining forces with the existing GI Alliance partner, Colorado Gastroenterology, in Denver. Denver Digestive Health Specialists (DDHS) consist of six board-certified gastroenterologists. Focused on a multi-disciplinary approach, DDHS is one of Denver’s premier gastroenterology practices. Partnering with GI Alliance provides DDHS with dedicated infrastructure and operational enhancements, allowing physicians to serve their patients better.
The average incentive bonus in 2021 for gastroenterology was $60,000, according to Physicians Thrive 2022 Physician Compensation Report. The report, released Jan. 27, outlines compensation and hiring trends and helps physicians collect industry data to analyze the current healthcare landscape. Of the specialists surveyed, 55 percent reported receiving an incentive bonus in 2021.
DALLAS, Jan. 25, 2022 /PRNewswire/ — GI Alliance, the nation’s largest independent gastroenterology services organization, is pleased to announce the formation of a new joint venture with United Surgical Partners International (USPI). The joint venture holds a majority position in two endoscopy centers co-owned by GI Alliance’s physician partners: GAB Endoscopy Center in San Antonio, TX, and South Plains Endoscopy Center in Lubbock, TX.
A three-drug combination demonstrated activity for patients with microsatellite-stable, BRAF V600E-positive metastatic colorectal cancer, according to study results presented at ASCO Gastrointestinal Cancers Symposium.
In a recent study, investigators showed that a culturally tailored patient navigation program can improve the rate of colorectal cancer screening among Hispanic adults and potentially help eliminate historical gender disparities in such screening. The findings are published by Wiley online in Cancer.
Registration is now open for the Gut Microbiota for Health (GMFH) World Summit 2022, taking place March 12-13 in Washington, D.C., and virtually. Organized by AGA and the European Society of Neurogastroenterology and Motility (ESNM), the GMFH World Summit is the preeminent international meeting on the gut microbiome for clinicians, dietitians and researchers.
Drugs which are commonly-used as the first line of treatment for colorectal cancer cause the tumor cells to oversecrete mucins, according to a new study (“Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion”) published in eLife. The proteins alter the mucous layer, forming a physical barrier that prevents drugs from reaching their intended target.